LUND, SWEDEN and LEIDEN, THE NETHERLANDS--(Marketwire - September 29, 2011) - NeuroVive
Pharmaceutical AB (publ) and to-BBB, the Dutch brain drug delivery company,
have been awarded a grant of EUR1 million through the Eureka Eurostars
program for the joint development of therapies for stroke and other acute
Stroke is the leading cause of adult disability in Europe, imposing a large
economic burden on individuals and society. Currently, the development of
and effective neuroprotective treatments represents the greatest unmet need
the management of stroke.
The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB
technologies, two highly innovative European Small and Medium Enterprises
(SMEs), a grant of approximately EUR500,000 each. This grant supports their
preclinical development program on a potential new treatment for stroke
patients. In this program NeuroVive's cyclosporin A for the treatment of
neurological damage is combined with to-BBB's G-Technology® to enhance
of this drug across the blood-brain barrier. The strategic collaboration
the two companies commenced in October 2010 and the Eurostars grant
and accelerates this partnership.
"NeuroVive's expertise in the area of acute neurological conditions and
leading clinical work with NeuroSTAT® in traumatic brain injuries,
strong base for this program." says Pieter Gaillard, CSO of to-BBB, "Since
blood-brain barrier limits drug penetration in stroke patients when they
most, to-BBB's proprietary G-Technology® holds promise to enhance
of cyclosporin-based pharmaceuticals for this devastating disorder."
"We are proud that our innovative partnership has been recognized by the
Eurostars program. Our project received ranking position 20 out of 348
initiatives in a strong competitive environment. We look forward to
the partnership of NeuroVive and to-BBB with the aim to generate therapies
the large stroke market and other acute neurological conditions", says
Bronnegard, CEO of NeuroVive.
Eurostars aims to stimulate SMEs to lead international collaborative
and innovation projects by easing access to support and funding. It is
tuned to focus on the needs of SMEs, and specifically targets the
new products, processes and services and the access to transnational and
NeuroVive Pharmaceutical AB (publ) is a Swedish drug development company.
NeuroVive's primary mission is to develop drugs for the treatment of acute
injury, reperfusion injury in myocardial infarction and other acute
where mitochondrial energy production is critical for clinical outcome. The
company is currently sponsoring a phase III clinical trial with its
A lipid emulsion in heart attack patients, and is entering into a phase II-
clinical trial in traumatic brain injury. In addition to the cyclophilin-D
program, NeuroVive is developing additional medications treating
dysfunction (i.e., reduced or limited energy production), and disorders
requiring an increased energy demand such as recovering from extensive
and intensive care, and as well conditions in which augmented energy
(e.g. obesity) is important.
NeuroVive Pharmaceutical AB (publ) shares are listed on the Swedish trading
platform AktieTorget (www.aktietorget.se). The AktieTorget market is
emerging, entrepreneurial businesses and offers an electronic trading
supplied by the OMX Nordic stock exchange in Stockholm, Sweden.
to-BBB is a clinical stage biotechnology company focusing on enhanced drug
delivery across the blood-brain barrier. The Company is developing novel
treatments for devastating brain disorders, such as brain cancer,
neurodegenerative diseases and lysosomal storage diseases, by combining
drugs with the G-Technology®, to-BBB's proprietary brain delivery
technology combines the widely used drug delivery approach of pegylated
liposomes with the endogenous tripeptide glutathione as targeting ligand in
novel and safe way. Together with several top tier pharma and biotech
to-BBB is investigating the versatility of the G-Technology® for drugs
unable to reach the brain within a tolerable therapeutic window. to-BBB is
applying the G-Technology® for the delivery of doxorubicin for the
brain cancer as its internal lead product 2B3-101.
to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park
established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei,
Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud
International, the Industrial Bank of Taiwan Management Corporation (IBTM)
consortium of informal investors.
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NeuroVive Pharmaceutical AB via Thomson Reuters ONE